Saturday, September 5

Browsing: DESTINYBreast06

Support

142 Exploratory Biomarker Analysis of Trastuzumab Deruxtecan Versus Physician’s Choice of Chemotherapy in HER2-Low/Ultralow, Hormone Receptor–Positive Metastatic Breast Cancer in DESTINY-Breast06

By NewsCancerApril 30, 20260

BackgroundDESTINY-Breast06 (NCT04494425), a randomized, open-label, phase 3 trial, demonstrated a clinically meaningful progression-free survival (PFS) benefit with trastuzumab deruxtecan (T-DXd)…

Survivors

141 DESTINY-Breast06 Post Hoc Analysis by Physician’s Choice of Chemotherapy: Efficacy and Safety of Trastuzumab Deruxtecan Versus Physician’s Choice of Chemotherapy in Hormone Receptor–Positive, HER2-Low or -Ultralow Metastatic Breast Cancer

By NewsCancerApril 30, 20260

BackgroundDESTINY-Breast06 is a randomized, open-label phase 3 trial in patients with hormone receptor–positive (HR+), HER2-low (immunohistochemistry [IHC] 1+ or IHC…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.

What's Hot

PD-L1 expression and survival in unresectable/recurrent gastric cancer treated by 1st-line treatment without immune checkpoint inhibitors: JCOG1013A1

Managing High-Risk BCLC-C HCC in a Younger Fit Patient

CELMoD Potency and Cereblon-Mediated Activity in Multiple Myeloma

Browsing: DESTINYBreast06

142 Exploratory Biomarker Analysis of Trastuzumab Deruxtecan Versus Physician’s Choice of Chemotherapy in HER2-Low/Ultralow, Hormone Receptor–Positive Metastatic Breast Cancer in DESTINY-Breast06

141 DESTINY-Breast06 Post Hoc Analysis by Physician’s Choice of Chemotherapy: Efficacy and Safety of Trastuzumab Deruxtecan Versus Physician’s Choice of Chemotherapy in Hormone Receptor–Positive, HER2-Low or -Ultralow Metastatic Breast Cancer

PD-L1 expression and survival in unresectable/recurrent gastric cancer treated by 1st-line treatment without immune checkpoint inhibitors: JCOG1013A1

Managing High-Risk BCLC-C HCC in a Younger Fit Patient

CELMoD Potency and Cereblon-Mediated Activity in Multiple Myeloma

<![CDATA[Conclusions and Award Ceremony]]>

PD-L1 expression and survival in unresectable/recurrent gastric cancer treated by 1st-line treatment without immune checkpoint inhibitors: JCOG1013A1

Managing High-Risk BCLC-C HCC in a Younger Fit Patient

CELMoD Potency and Cereblon-Mediated Activity in Multiple Myeloma

<![CDATA[Conclusions and Award Ceremony]]>

Latest Post

PD-L1 expression and survival in unresectable/recurrent gastric cancer treated by 1st-line treatment without immune checkpoint inhibitors: JCOG1013A1

Managing High-Risk BCLC-C HCC in a Younger Fit Patient

CELMoD Potency and Cereblon-Mediated Activity in Multiple Myeloma

Subscribe to Updates

What's Hot

Browsing: DESTINYBreast06